UNSPSC 51294503: Brofaromine

This classification denotes a monoamine oxidase inhibitor with the molecular formula C14H16BrNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6WV4B8Q07H, chemically known as piperidine, 4-(7-bromo-5-methoxy-2-benzofuranyl)-, hydrochloride but generally known as brofaromine, which bears US NIH Compound Identifier 44571. Brofaromine most often comes in base and hydrochloride forms. European Medicines Agency schedules Brofaromine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05899MIG.

UNSPSC 51294503 Brofaromine is a Commodity code that in recent state and local procurement shows limited activity aligned with its pharmaceutical scope. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS posted June 30, 2026—requests naloxone and drug deactivation systems rather than brofaromine itself, suggesting either a data-classification mismatch or that brofaromine procurement through state and local channels remains minimal. County health and community services departments appear to be the primary issuing bodies when pharmaceutical or emergency-response products are tagged to this code, though the sparse opportunity record provides limited visibility into repeat purchasing patterns or issuing-body mix across other jurisdictions.

Seminole County's June 2026 solicitation stands as the only recent activity visible under this code. The county sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida and a response deadline of July 26, 2026. The contract carried an initial two-year term with a one-year renewal option, fixed-fee pricing, E-Verify compliance, and potential FEMA funding contingencies. The narrow recent-opportunity record and the mismatch between the code's nominal pharmaceutical name and the actual health-system procurement documented here signal that brofaromine-specific state and local buying activity remains either highly selective or underrepresented in current solicitation data.